Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by wofatson Jan 16, 2023 3:06pm
139 Views
Post# 35226291

RE:Increase by country 2020 to 2021

RE:Increase by country 2020 to 2021Sorry ,to be long winded 
The share price has settled at 550ish since October 2020.  It seems that there is no well known advisers taking up the mantle and promoting the stock but that should change as the EBITDA and the EPS get larger . More drugs are added and sales from them will be eventually in every country.

Will not the loan they took out with IFC will be paid back with the Latin American currencies that someone has been saying are devalued. Isn't that how business is done? Is that bad business?

They are up against their own sales and profit numbers now . This is what shareholders have bought in for . The next 3 years will be telling the tale.  I do not think they can not do well .

One last thing . If people invest in stock or don't by the info gleaned from Stockhouse bulletin boards, especially this one, well you know.


<< Previous
Bullboard Posts
Next >>